---
title: "Nomura Raises REMEGEN  TP to HKD89.44, Maintains Neutral Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293895316.md"
description: "Nomura raised REMEGEN'starget price to HKD89.44 from HKD79.64, maintaining a Neutral rating. The firm forecasts 2Q26 revenue of RMB2.7 billion and net profit of RMB1.6 billion, driven by high gross margins. Although FY2026 revenue forecasts were lowered by 4.8%, earnings estimates rose 8.4% due to non-recurring gains. Investors are advised to monitor overseas clinical progress for RC18 and RC148."
datetime: "2026-07-27T07:37:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293895316.md)
  - [en](https://longbridge.com/en/news/293895316.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293895316.md)
generator: "portal-rs"
---

# Nomura Raises REMEGEN  TP to HKD89.44, Maintains Neutral Rating

Nomura published a report expecting REMEGEN (09995.HK) +2.600 (+3.125%) Short selling $8.57M; Ratio 8.487% 's 2Q26 revenue to reach RMB2.7 billion. Gross margin is forecast at 96.2%, up 11.4 ppts YoY, while operating expenses are expected to rise 24% YoY to RMB806 million, including R&D expenses of RMB403 million and selling expenses of RMB322 million, to support new trials and strengthen sales efforts. Net profit is projected at RMB1.6 billion, compared with a loss of RMB195 million in the same period last year.

Nomura raised its TP on REMEGEN (09995.HK) +2.600 (+3.125%) Short selling $8.57M; Ratio 8.487% from HKD79.64 to HKD89.44 and maintained its Neutral rating. It lowered its FY2026 revenue forecast by 4.8%, while raising its earnings forecast by 8.4% due to higher non-recurring gains in 1Q26. Investors are advised to continue closely monitoring the overseas clinical progress of RC18 and RC148 in 2H26. (ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-27 12:25.)

### Related Stocks

- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [8604.JP](https://longbridge.com/en/quote/8604.JP.md)
- [NMR.US](https://longbridge.com/en/quote/NMR.US.md)

## Related News & Research

- [J.P. Morgan Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)](https://longbridge.com/en/news/295287684.md)
- [RemeGen Shareholders Back All Resolutions at 2025 AGM](https://longbridge.com/en/news/289949552.md)
- [Impact Therapeutics schedules board meeting to review interim results](https://longbridge.com/en/news/296324936.md)
- [SinoMab BioScience schedules board meeting to review interim results](https://longbridge.com/en/news/296344299.md)
- [Novem Group held annual general meeting, 89% of voting capital represented](https://longbridge.com/en/news/296480355.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**